Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
Date:11/2/2011

CAMBRIDGE, Mass., Nov. 2, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2011. At September 30, 2011, Idenix's cash and cash equivalents totaled $64.7 million.

Third Quarter and Nine Month 2011 Financial Results
For the third quarter ended September 30, 2011, Idenix reported total revenues of $2.6 million, compared to total revenues of $3.8 million in the third quarter of 2010. The Company reported a net loss of $11.7 million, or a loss of $0.12 per basic and diluted share, for the third quarter ended September 30, 2011, compared to a net loss of $12.9 million, or a loss of $0.18 per basic and diluted share for the third quarter ended September 30, 2010.

For the nine months ended September 30, 2011, Idenix reported total revenues of $7.7 million, compared to total revenues of $7.8 million in the nine months ended September 30, 2010. The Company reported a net loss of $33.9 million, or a loss of $0.39 per basic and diluted share, for the nine months ended September 30, 2011, compared to a net loss of $45.4 million, or a loss of $0.65 per basic and diluted share for the nine months ended September 30, 2010. The $11.5 million reduction in net loss in 2011 was due primarily to $5.5 million of lower expenses related to devoting fewer resources to our protease inhibitor and non-nucleoside polymerase inhibitor programs during 2011, $3.1 million lower salaries and personnel related costs, $2.6 million of lower costs related to the timing of clinical trials of IDX184 and $2.2 million of non-recurring restructuring expenses in 2010. Offsetting these amounts was an increase of $3.7 million in expenses related to the preclinical devel
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 Kinex Pharmaceuticals announced today ... at Roswell Park Cancer Institute. KX2-361 (KX02), ... that has shown potent inhibitory activity against a broad ... are resistant to Temozolomide (T98G), the most widely used ... well-established brain tumor mouse model, KX2-361 consistently clears brain ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... R.I., June 14, 2011 CVS/pharmacy ... options at more than 7,200 convenient locations nationwide. Shoppers have ... a larger-than-ever selection of gifts, goods and everyday needs. From ... offers the hottest gear and thoughtful keepsakes perfect for every ...
... Inc. (NYSE AMEX: ULU), a specialty pharmaceutical ... management and oral care products, today announced it has completed ... Company,s Chairman, President, and Chief Executive Officer. The Company intends ... The convertible notes will bear interest at the rate of ...
Cached Medicine Technology:Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 2Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 3ULURU Inc. Raises $140,000 in Convertible Debt Offering 2
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... 25, 2014 BambooFlooringChina.com sells many bamboo ... bamboo flooring. Today, the company announces big discounts ... styles and colors. , BambooFlooringChina.com is the world’s leader ... promotion is valid until Jan. 20, 2015. , The ... woven with a natural thread. All the bamboo strips ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... GlaxoSmithKline (NYSE: GSK ) is prepared with ... Inhalation Powder ( www.RELENZA.com ) to meet public health ... to newly updated influenza activity data ( http://www.cdc.gov/flu/weekly/ ) ... (CDC), the flu virus is widespread in 27 states. ...
... March 2 Join Jacqueline Foreman, host of Your Mental ... best-selling author John Gray whose first book Men Are ... copies worldwide. They will discuss his new book ... Men and Women Cope Differently with Stress on Thursday, ...
... March 2 /PRNewswire/ -- The Healthcare business ... the national healthcare alliance, as its preferred vendor for ... vendor designation, Thomson Reuters is authorized to sell its ... Clinical Xpert has been named the KLAS Category Leader ...
... special protein sequence, the so-called PARF motif, on their ... Singh Chhatwal and his colleague Patric Nitsche-Schmitz of the ... the role played by PARF in the development of ... a test system that is able to recognise and ...
... N.J., March 2 Managed Health Care Associates, Inc. ... announced the launch of a new website www.mhainc.com ... look more representative of MHA,s strong brand and leadership ... the latest information on MHA core businesses and supporting ...
... New CompactRIO Controller and Five FPGA-Based Chassis are Ideal ... Texas, March 2, 2009 National Instruments (Nasdaq: ... prototyping hardware that makes it possible for engineers and ... time to market and lower development costs. The five ...
Cached Medicine News:Health News:Ample Supplies of Relenza Available as Flu Season Peaks 2Health News:Ample Supplies of Relenza Available as Flu Season Peaks 3Health News:John Gray Will Discuss His New Book Why Mars and Venus Collide 2Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 2Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 3Health News:Help for children with sick hearts 2Health News:MHA Announces: Launch of New Website 2Health News:National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs 2Health News:National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs 3Health News:National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs 4
LOGIQ Book XP provides you the next generation performance in a compact platform....
The Rio Catheter is designed to simplify your intravascular interventions by removing thrombus and restoring epicardial flow to the procedure....
... Guidant VASOVIEW® HemoPro™ EVH system ... new level of performance in ... the saphenous vein and radial ... it lets you make a ...
Patient Monitor...
Medicine Products: